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Hepato-pancreato-biliary (HPB) tumors are common in China. However, these tumors are often diagnosed at intermedi-
ate/advanced stages because of the lack of a systemic surveillance program in China. This situation creates many technical 
challenges for surgeons and increases the incidence of postoperative complications. Therefore, Dr. Xiao-Ping Chen has made 
many important technical improvements, such as Chen’s hepatic portal occlusion method, the anterior approach for liver resec-
tion of large HCC tumors, the modified technique of Belghiti’s liver-hanging maneuver, inserting biliary-enteric anastomosis 
technique, and invaginated pancreaticojujunostomy with transpancreatic U-sutures. These techniques are simple, practical, and 
easy to learn. Owing to these advantages, complicated surgical procedures can be simplified, and the curative effects are 
greatly improved. These improved techniques have been widely applied in China and will benefit many additional patients. In 
this review, we introduce our experience of surgically treating intermediate/advanced hepatocellular carcinoma (HCC), hilar 
cholangiocarcinoma (HC), and pancreatic carcinoma, mainly focusing on technical innovations established by Dr. Chen in 
HPB surgery. 
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Hepato-pancreato-biliary (HPB) tumors are very common 
diseases in China. These tumors are usually aggressive and 
have poor prognosis. Surgery is the only potential curative 
therapy for these malignancies. The most common form of 
tumor in the liver is hepatocellular carcinoma (HCC), which 
commonly results from hepatitis B virus infection and is 
prone to be diagnosed at intermediate/advanced stages ow-
ing to the lack of a systemic surveillance program in China. 
Intermediate/advanced HCC, particularly a huge HCC tu-
mor, creates many technical challenges for surgeons. Hilar 
cholangiocarcinoma and pancreatic head carcinoma are ex-
tremely malignant tumors, which usually cause obstruction 
of the bile duct, leading to deterioration in the patient’s 
general condition. Surgery is technically challenging for 
these tumors. Therefore, technical innovations for surgical 
treatment of these malignant tumors are urgently needed to 
improve the operative safety and long-term outcomes of 
these diseases in China. 
A recent national survey in China (unpublished data, re-
search code 201043901), involving 75 hospitals and 30,536 
patients with HCC, found that 43.1% of patients had a tu- 
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mor larger than 5 cm and 22.5% had a tumor larger than  
10 cm in diameter at their first visit to a doctor. About 
one-third of patients with a large HCC tumor displayed 
portal hypertension or invasion of the portal vein by the 
tumor. In such cases, nonsurgical treatment, such as 
transcatheter arterial chemoembolization (TACE) and/or 
systemic treatment, results in poor long-term survival rates. 
However, studies have shown that liver resection improves 
the long-term survival of patients with large HCC tumors or 
intermediate/advanced HCC. Over the past few decades, 
liver resection for HCC has evolved to become safe, with a 
low operative mortality rate, and at the Hepatic Surgery 
Center of Tongji Hospital, liver resection is routinely rec-
ommended to patients with large HCC tumors, irrespective 
of the size of the tumor or the presence of portal hyperten-
sion or portal vein tumor thrombosis (PVTT). Patients who 
undergo surgery show significant improvements in their 
long-term survival rate compared with patients who receive 
non-surgical treatment. 
Malignancies at the hepatic hilus and the head of the 
pancreas have poor prognoses. Surgery is the only possible 
curative treatment that may prolong survival. However, the 
rate of postoperative complications is very high. Bile duct 
or pancreas reconstruction with intestine is the major in-
traoperative difficulty as well as the main reason for post-
operative complications, including bleeding, infection, liver 
failure, bile leakage, and pancreatic fistula. Chen recom-
mends minor hepatic resection and applies an inserting bili-
ary-enteric anastomosis technique for HC. The long-term 
survival was comparable, while postoperative complications 
were significantly reduced. For pancreatic cancer, we used 
Chen’s invaginated pancreaticojejunostomy with transpan-
creatic U-sutures, a simple technique that reduced postoper-
ative pancreatic fistula (POPF). 
Owing to his outstanding contribution to HPB surgery, 
Dr. Chen had been elected as an academician of the Chinese 
Academy of Science in 2015. This review is mainly focused 
on Chen’s major contribution to HBP surgery.  
HEPATOCELLULAR CARCINOMA 
Large hepatocellular carcinoma 
Although there is no universally accepted definition of a 
large HCC tumor, we have defined it as a tumor greater than 
5 cm in diameter; a “huge” HCC tumor is deemed to be a 
tumor greater than 10 cm in diameter. A significant propor-
tion of patients present with large HCC tumors at initial 
diagnosis in our institution. The 5-year survival rates after 
liver resection range from 28% to 42% for HCC tumors >5 
cm and from 17% to 32% for HCC tumors ≥10 cm; these 
results are significantly superior to the 5-year survival rates 
after TACE. Unfortunately, liver resection in a patient with 
a large HCC tumor is associated with a high risk of 
post-operative liver failure and a significantly high recur-
rence rate. Post-operative morbidity rates range from 27% 
to 33.8%, mortality rates range from 2.4% to 6.0% and 
5-year recurrence-free survival rates range from 20% to 
26% (Zhong et al., 2014).  
Chen believes that hepatectomy for large or huge HCC 
removes relatively less normal liver parenchyma, while 
hepatectomy for small HCC removes more normal liver 
parenchyma (Chen, 1994). The remnant liver parenchyma 
in the tumor located lobe is relatively reduced due to pres-
sure or destruction by the tumor, while the healthy liver 
lobe undergoes compensative proliferation as a result. 
Therefore, the remnant liver is possibly sufficient even after 
removing the huge HCC. With advances in surgical tech-
niques, large or huge HCC tumors are no longer a contrain-
dication to liver resection. From January 1990 to December 
2003, 2,102 patients with large HCC tumors underwent liv-
er resection at our center (Chen et al., 2006a). These pa-
tients were divided into two 7-year periods: before the end 
of December 1996 and after December 1996. The 5-year 
disease-free and overall survival rates were 23.8% and 
38.7%, respectively, in group 2, and 18.9% and 27.9%, re-
spectively, in group 1. This study demonstrated that liver 
resection in patients with large HCC tumors can result in 
good long-term outcomes. 
The incidence of post-hepatectomy liver failure is closely 
correlated with the volume and function of the remnant liv-
er. Liver resection in a patient with a large HCC tumor gen-
erally involves the removal of the tumor along with the sur-
rounding liver parenchyma. Compensatory hypertrophy 
usually occurs in the contralateral liver, even in the presence 
of cirrhosis, thus supporting the use of major resection in 
patients with large or even huge HCC tumors. A systematic 
review found that 50.9%–96.2% of patients with a huge 
HCC tumor are treated by major resection, and this figure is 
76.3% at our center. When selecting patients with large 
HCC tumors for liver resection, accurate evaluations of liv-
er functional reserve and remnant liver volume are essential; 
the Child-Pugh classification alone is not sufficient to de-
fine the safe limit of extent of liver resection. At our center, 
liver resection for a huge HCC tumor is only performed in 
the presence of good cardiopulmonary and renal functions, 
Child-Pugh grade A, and a retention rate of indocyanine 
green at 15 min (ICG-R15) of less than 15% (Chen et al., 
2006a). Computed tomographic (CT) volumetry is also used 
in determining whether the remnant liver volume is    
adequate. A combination of CT volumetric measurement 
and ICG-R15 can provide a better index for selecting pa-
tients for major liver resection. Recently, we retrospectively 
studied 996 patients with chronic hepatitis B or C who un-
derwent liver resection for HCC and found that total cho-
lesterol level was significantly correlated with post-    
operative complications. Patients with low cholesterol level 
(<2.8 mmol L1) had worse pre-operative liver functional 
reserves and had more post-operative complications than 
patients with normal cholesterol levels (≥2.8 mmol L1) 
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(Wang et al., 2014).  
Resection of a large HCC tumor is technically challeng-
ing, especially if the tumor is in the right side of the liver 
and is larger than 10 cm. A large tumor also poses difficul-
ties in the control of hepatic veins before or during liver 
transection. Thus, patients with a large HCC tumor tend to 
have more intra-operative blood loss, more blood transfu-
sions, and longer operation time. Since 1987, our center has 
implemented the anterior approach (parenchymal transec-
tion without prior mobilization of the liver) for liver resec-
tion of a large HCC tumor. Pringle’s maneuver is routinely 
used to occlude the hepatic inflow. For difficult hepatecto-
mies, the hepatic pedicle and the inferior vena cava below 
the liver are clamped simultaneously for better hepatic vas-
cular inflow and outflow control (Chen’s method). The liver 
parenchyma is transected using a finger-fracture technique 
in the early period. Up-to-date instruments are used, such as 
the BiClamp, cavitron ultrasonic surgical aspirator (CUSA), 
microwave coagulator, ultrasonic scalpel, water-jet dissec-
tor, and ligasure vessel sealing system. After splitting the 
liver in the midplane, the liver is then mobilized by dividing 
the ligaments. This resection method avoids laceration of 
major vessels during early liver mobilization as well as the 
rupture of large tumors owing to excessive traction. In addi-
tion, delaying liver mobilization until near the end of the 
operation prevents excessive bleeding from retroperitoneal 
venous collaterals that have opened up in patients with cir-
rhosis and portal hypertension. Importantly, this resection 
method follows the oncological principle of a no-touch 
technique by ligating vessels before the excessive handling 
of tumors, thus minimizing shedding of tumor cells into the 
bloodstream and preventing metastatic seeding. Patients 
with a large HCC tumor who are treated with liver resection 
using this method have significantly better long-term out-
comes.  
Dr. Chen has established several techniques for liver re-
section in patients with a large HCC tumor. For anatomical 
right or left hemihepatectomy, a simple technique has been 
developed by directly ligating the corresponding inflow and 
outflow pedicles of the hemiliver to be resected without 
prior hilar dissection. He has also established a liver dou-
ble-hanging maneuver that is a modification of Belghiti’s 
liver-hanging maneuver (Figure 1). Recently, these tech-
niques have been applied to laparoscopic hepatectomy and 
da Vinci robotic hepatectomy at Tongji Hospital. His 
method is an improvement because the tunnel is set up 
through a retrohepatic avascular plane on the right of the 
inferior vena cava. It is easy to perform and has a high suc-
cess rate and a low chance of inducing bleeding when mak-
ing the tunnel. With the use of these effective methods, our 
operative mortality is now 0.7%, compared with 2.4%– 
6.0% in other large HCC series. 
Multiple hepatocellular carcinoma 
According to the Barcelona Clinic Liver Cancer (BCLC) 
staging system and treatment recommendations, TACE is 
the treatment of choice for multiple HCC tumors (except 
when there are fewer than three tumors and they are each 
smaller than 3 cm in diameter, in which case the treatment 
recommendation is liver transplantation or ablation with 
percutaneous ethanol injection (PEI) or radiofrequency ab-
lation (RFA). However, the long-term outcomes of TACE 
treatment in such cases are dismal.  
Liver resection in patients with multiple HCC tumors 
remains controversial. In Western countries, liver resection 
is usually indicated for a solitary HCC tumor because resec-
tion of multiple tumors carries a high recurrence risk and 
results in unfavorable survival outcomes. In contrast, liver 
resection for multiple tumors has been attempted in up to 
20% of all liver resections for HCC at our center (Chen et 
al., 2006a). Despite the increased risk of recurrence in pa-
tients with multiple lesions, the evidence suggests that liver 
resection is justified in carefully selected patients. Several 
surgical series on a small number of patients with large and 
multiple HCC tumors have reported a median survival 
ranging from 9.8 to 12 months. Thus, in the era of modern 
surgery, with appropriate patient selection, even multiple 
HCC tumors are not a contraindication for liver resection.  
For multiple tumors, liver resection usually needs to be 
combined with local ablative therapies to destroy tumors in 
the contralateral hemiliver. The strategies for treating mul-
tiple tumors at our center include en bloc resection of all 
tumors in one hemiliver; resection of a large tumor in one 
hemiliver combined with wedge resection of a smaller le- 
 
 
Figure 1  (Color online) Liver double-hanging maneuver and a simple technique for ligating of inflow and outflow vessels without hilar dissection during 
hepatectomy. A, Chen’s modified liver double-hanging maneuver in da Vinci robotic hepatectomy. B and C, Ligation of inflow and outflow vessels without 
hilar dissection during anatomical right hepatectomy. B, Ligation of the right hemihepatic pedicle. C, Ligation of the right hepatic vein. 
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sion; or local ablation of centrally or deeply located tumors 
in the other hemiliver. Combining local ablation with liver 
resection has been found to be a safe and effective strategy 
to treat multiple HCC tumors. 
Multiple HCC tumors may result from multicentric oc-
currence (MO) or intrahepatic metastasis (IM). Studies have 
suggested that IM occurs more commonly from tumors with 
PVTT, in multiple satellite nodules surrounding a main tu-
mor or when a satellite tumor near a main tumor shows sim-
ilar or poorer histological differentiation when compared 
with the main tumor. Multiple HCC tumors that do not meet 
these criteria are more likely to result from de novo MO. 
The prognosis after liver resection for HCC with MO is 
usually better than for HCC with IM. Thus, HCC with syn-
chronous or metachronous MO represents an indication for 
liver resection. Discrimination of IM and MO is important 
because, in general, HCC that has acquired metastatic abil-
ity exhibits more aggressive biological behavior, thus in-
fluencing therapeutic strategy decisions. Molecular biologi-
cal studies are the only way to be certain that multiple HCC 
tumors have MO or IM origin. More studies should be con-
ducted aiming to differentiate IM from MO to further im-
prove surgical outcomes. 
Hepatocellular carcinoma with portal vein tumor 
thrombosis 
HCC tends to invade adjacent venous tributaries, which is 
associated with an increased risk of intrahepatic or extrahe-
patic metastases. PVTT (including thrombosis in the sec-
ondary/primary portal branches or the main portal trunk) is 
present in 5.3%–15.4% of patients undergoing liver resec-
tion, 11.3%–38.0% of patients receiving non-surgical 
treatment and 32.0%–62.2% of autopsy cases (1994). PVTT 
is the most predictive factor of poor survival in patients with 
HCC. According to the American Association for the Study 
of Liver Diseases (AASLD) and the European Association 
for the Study of the Liver (EASL) guidelines for HCC 
management, patients with PVTT are not candidates for 
either surgical treatment or TACE, and only palliative ther-
apies are recommended. The median survival rate for un-
treated HCC with PVTT is 2.7 months (Llovet et al., 1999). 
TACE only achieves 5-year survival rates of 0%–6.1% for 
HCC with PVTT, and the outcomes of other non-surgical 
treatments, including sorafenib, are disappointing (Chen et 
al., 2006b; Llovet et al., 1999). Previous studies have shown 
liver resection to be a safe and effective treatment for HCC 
with PVTT if patients are carefully selected. In a retrospec-
tive series at our center including 438 patients with HCC 
and PVTT who underwent liver resection, the 1-, 3- and 
5-year survival rates were 52.1%, 16.0% and 11.8%, re-
spectively (Chen et al., 2006b). If only patients with PVTT 
in the primary or secondary branches of the main portal 
trunk were considered, the 1-, 3-, and 5-year overall surviv-
al rates were 58.7%, 22.7%, and 18.1%, respectively  
(Figure 2). 
 
Figure 2  (Color online) Survival curves showing the overall survival 
rates of group A (PVTT was located in the hepatic resection area or pro-
truded into the first branch of the main portal vein beyond the resection 
line for <1 cm) and group B (PVTT extended into the main portal vein). A 
significant difference is observed between the two curves (log-rank test; 
P<0.0164) (Chen et al., 2006b).  
It has now been generally accepted in Asian countries 
that when PVTT is confined to the primary branch of the 
main portal trunk, the tumor and PVTT can be completely 
removed by liver resection, with resection of the ipsilateral 
portal vein branch containing the tumor thrombus. When 
the tumor thrombus has extended to the main portal trunk, 
surgical resection is usually not considered. However, our 
experience shows that concomitant liver resection and 
thrombectomy can safely be performed in selected patients 
with HCC and PVTT extending to the main portal trunk, 
provided that the patients have preserved liver function and 
the tumors are resectable; such operations have 1-, 2-, and 
3-year overall survival rates of 39.5%, 20.4%, and 5.7%, 
respectively. Although concomitant liver resection and 
thrombectomy is a palliative treatment, it still offers sub-
stantial benefit in selected patients with HCC and tumor 
thrombosis in the main portal trunk. Liver resection in such 
patients may provide the following benefits: decreased por-
tal venous pressure, improved liver function, prolonged 
survival, and improved quality of life. 
Hepatocellular carcinoma with portal hypertension 
The surgical indications for patients with HCC and portal 
hypertension remain controversial. Based on the BCLC 
staging system and the National Comprehensive Cancer 
Network (NCCN) guidelines for treatment of HCC, liver 
resection is contraindicated in patients with portal hyperten-
sion, as this condition is associated with a high incidence of 
post-operative liver decompensation and a poor survival 
rate. Recently, some authors have been advocating liver 
resection for patients with HCC and portal hypertension. 
The reported 5-year overall survival rates after liver resec-
tion vary from 25% to 51.5% in patients with portal hyper-
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tension and from 50% to 70% in patients without portal 
hypertension. Our retrospective clinical study also provided 
important evidence that selected HCC patients with PHT 
could benefit from hepatic resection as compared with 
TACE or thermal ablation (Xiao et al., 2015). 
In China, 85%–90% of patients with HCC show various 
degrees of liver cirrhosis, and a large proportion of these 
patients present with clinical signs of portal hypertension. 
The potential risks of liver resection in patients with portal 
hypertension are liver decompensation, peri-operative vari-
ceal bleeding, and hemostatic disorders. To avoid these 
complications, at Tongji Hospital we routinely perform 
pre-operative upper gastrointestinal endoscopy to evaluate 
the risk of variceal bleeding and to limit the extent of liver 
resection. In selected patients, we perform splenectomy 
with or without devascularization of gastroesophageal  
varices.  
Our strategy for dealing with patients with HCC and cir-
rhotic hypersplenism is different from that of other centers. 
Usually, for patients with resectable HCC with splenomeg-
aly and hypersplenism, splenicarterial embolization is the 
treatment of choice to reduce splenic size and to control 
hypersplenism so that liver resection can safely be per-
formed. Some authors suggest that laparoscopic splenecto-
my should be carried out as a preliminary procedure to a 
second-stage liver resection. However, these two-stage op-
erations may cause complications and prolong hospital stay. 
To solve this problem, we conducted a study in patients 
with resectable HCC and hypersplenism in order to compare 
the outcomes of simultaneous liver resection and splenec-
tomy (the LS group) with those of liver resection only (the 
L group). There was no surgical death in either of these 
groups, and there was no significant difference in the inci-
dences of complications. Patients in the LS group had a 
significantly higher 5-year recurrence-free survival rate 
compared to the L group (37.2% vs. 27.2%). There was no 
significant difference in overall 5-year survival rates be-
tween the two groups (Chen et al., 2005) (Figure 3).  
These data indicate that not only is it safe to use simul-
taneous liver resection and splenectomy to treat patients 
with HCC and hypersplenism, this approach is therapeuti-
cally superior to liver resection alone. When an enlarged 
spleen associated with hypersplenism is removed, white 
blood cells and platelet counts return to normal levels; this 
favors the use of post-operative adjuvant chemotherapy, 
which may help to decrease tumor recurrence and might 
account for a lower recurrence-free survival rate in the LS 
group. Furthermore, simultaneous liver resection and sple-
nectomy does not weaken the patients’ immunological 
function; on the contrary, it is associated with homeostasis 
of T cell subsets and T helper 1 cytokines in the early 
post-operative period. Therefore, the immunological func-
tion in patients with HCC might be improved following 
splenectomy, which might contribute to a better antitumor 
immunological function and a decreased tumor recurrence 
 
Figure 3  (Color online) Disease-free survival curves of patients with 
hepatocellular carcinoma undergoing liver resection and splenectomy (the 
LS group) or liver resection alone (the L group). (Chen et al., 2005). 
rate.  
Although liver resection in association with splenectomy 
with or without devascularization of gastroesophageal vari-
ces can be performed safely in patients with HCC and portal 
hypertension, these complex procedures are likely to lead to 
post-operative complications, particularly post-operative 
liver failure, because patients with cirrhosis tend to have 
poor liver functional reserve. As a consequence, the deci-
sion whether to perform liver resection or concomitant liver 
resection and splenectomy in patients with HCC and portal 
hypertension should be made very carefully. To ensure the 
safety of resection in patients with HCC and portal hyper-
tension, we pay special attention to evaluating the preopera-
tive liver function by using the ICG-R15 test, CT volumetry 
of the remnant liver, and the severity of cirrhosis. In patients 
with severe cirrhosis, limiting the extent of resection by 
non-anatomic resection is an effective way to prevent 
post-operative liver failure. 
Recurrent hepatocellular carcinoma 
The incidence of recurrence after liver resection is ex-
tremely high. The 5-year cumulative recurrence rates are 
77%–100%, and 80%–95% of recurrences are confined to 
the remnant liver (Huang et al., 2012). Effective therapeutic 
strategies for intrahepatic recurrence are critical in prolong-
ing survival after liver resection. The treatment algorithm 
for recurrent HCC varies, and no consensus has been 
reached. Treatment modalities for recurrent HCC include 
TACE, ablation therapy, repeat liver resection, salvage liver 
transplantation, and medical treatment. TACE is applicable 
to almost all patients with intrahepatic recurrences, and it 
plays an important role in the treatment of multiple recur-
rent HCC tumors. However, it is a palliative treatment, and 
long-term survival cannot be expected. Percutaneous abla-
tion therapies, such as PEI, RFA, and microwave coagula- 
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tion therapy (MCT) also play important parts in the man-
agement of recurrent HCC. RFA has been increasingly used 
as the preferred percutaneous therapy because of its effec-
tive local tumor control. Several studies showed that RFA 
achieved long-term outcomes similar to those of repeat liver 
resection in the treatment of intrahepatic recurrence after 
initial liver resection, especially in patients with no more 
than three recurrent tumor nodules of less than 3 cm in di-
ameter (Lau and Lai, 2009). RFA can be performed percu-
taneously, and its high repeatability renders it a preferred 
treatment option in selected patients with HCC recurrence. 
Recently, MCT has been reported to yield results similar to 
RFA for small recurrent HCC tumors. At our center, RFA 
and MCT are recommended for recurrent tumors smaller 
than 3 cm each and numbering three or less, situated deep in 
the liver. 
Repeat liver resection is also a good alternative treatment 
for recurrent HCC if a patient’s liver function is good. The 
5-year survival rate after repeat liver resection varies from 
23% to 69% in different studies, suggesting that repeat liver 
resection results in good outcomes in selected patients 
(Huang et al., 2012). However, the selection criteria of re-
peat liver resection for recurrent HCC remain vague and 
controversial. Some studies suggest that repeat liver resec-
tion is the treatment of choice for patients who have solitary 
recurrent HCC, who develop recurrence after a recur-
rence-free period of 1 year or more, and who show no vas-
cular invasion (Minagawa et al., 2003). Surgeons have re-
cently recognized that the types of HCC recurrence—that is, 
either metastases from a primary HCC (IM) or the devel-
opment of new HCC foci (MO) as a consequence of persis-
tent chronic active hepatitis and/or cirrhosis after liver re-
section—are the most important indicators for predicting 
long-term survival (Huang et al., 2012). Our study on the 
recurrent types of HCC revealed that repeat resection re-
sulted in better outcomes in patients with the MO type than 
in patients with the IM type (Huang et al., 2012). The 5-year 
overall survival rate after repeat resection for MO patients 
with recurrent HCC tumors of ≤5 cm was up to 56%. This 
survival rate was similar to that for patients with small HCC 
tumors after initial resection in other studies. However, for 
the IM patients with recurrent HCC tumors of ≤5 cm, the 
5-year overall survival rate after repeat resection was only 
8%. With close supervision after the initial resection, most 
recurrent HCC can be diagnosed at an early stage. Consid-
ering that only MO patients can expect a significant survival 
benefit from repeat resection, differentiation of the recurrent 
type is of great importance. Our previous study revealed 
that the recurrence-free time was the most important differ-
entiating factor between the IM and MO patients, and a re-
currence-free period of 18 months was the best cut-off time 
to differentiate between IM and MO (Figure 4). 	
Salvage liver transplantation (SLT) is another treatment 
of choice for recurrent HCC. It has been widely accepted 
that SLT should be used for patients who fulfill the Milan 
criteria. A study based on analysis of the European Liver 
Transplant Registry indicated that HCC recurrence in pa-
tients who previously underwent liver resection would often 
present with multiple tumor nodules, and only 25% of pa-
tients with recurrent tumors fulfilled the Milan criteria 
(Mergental and Porte, 2010). Studies also indicated that 
liver transplant was only feasible in 23% of patients with 
recurrent HCC (Adam et al., 2003). Our clinical data show 
that in patients with recurrent HCC beyond the Milan crite-
ria, the 3-year recurrence rate and overall survival rate after 
SLT are 86.1%, and 40.6%, respectively (Liang et al., 
2014). Our data suggest that SLT should not be recom-
mended to patients with recurrent HCC beyond the Milan 
criteria. 
LIVER TRANSPLANTATION 
According to a 2011 estimate, about 300,000 people in 
China develop end-stage liver disease each year. The only 
treatment available to these patients used to be whole-liver 
transplantation. However, many patients died due to a se- 
 
 
Figure 4  (Color online) The recurrence curves (A) and overall survival curves (B) of the multicentric occurrence (MO) group and intrahepatic metastasis 
(IM) group (Huang et al., 2012). 
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vere shortage of organ donors.  
To address the shortage, we began to develop living- 
donor liver transplantation, which involves surgically re-
moving a portion of the liver from a living donor. Because 
this technique does not require replacing the entire liver, 
one donor liver can be shared between two patients, thus 
mitigating the shortage of donor organs.  
Auxiliary liver transplantation can be used to treat some 
liver diseases but the success rate of these operations was 
low—about 10%—in the early 1980s. The primary reason 
for failure was that the limited space in the patient’s abdo-
men for the donor liver required the donor liver to be placed 
in an abnormal position, which was detrimental to the re-
construction of blood circulation. To address this problem, 
in 1983 we developed the first animal model for studying 
auxiliary partial orthotopic liver transplantation (Figure 5). 
The procedure involved cutting out 40% of the right liver of 
the canine model and transplanting a partial liver graft (37% 
of the total donor liver) onto the recipient liver. The proce-
dure solved the problem of space and enabled blood circula-
tion to be reconstructed effectively. Our successful experi-
ments and clinical applications in 13 cases demonstrated 
that the procedure was safe, effective and feasible. 
HILAR CHOLANGIOCARCINOMA  
Major or minor hepatic resection  
Hilar cholangiocarcinoma is the most common form of 
cancer to affect the biliary tract. Only a very few patients 
with unresectable, indolent and slow-growing hilar cholan-
giocarcinoma can achieve long-term survival (Ruys et al., 
2012). The prognosis of most patients with unresectable 
tumor is poor, with a median survival of less than 1 year, 
because of the vital position of the tumor. The treatment for 
hilar cholangiocarcinoma is challenging. Surgical treatment 
offers the only possibility of cure, and it requires removal of 
all tumor tissues with adequate resection margins. 
Common strategies for surgically treating hilar cholan-
giocarcinoma are hemihepatectomy with caudate lobectomy  
 
 
Figure 5  (Color online) In 1983, Chen developed the first canine model 
of auxiliary partial orthotopic liver transplantation. 
or extended hemihepatectomy, a procedure that involves 
60%–80% resection of the liver. However, extensive resec-
tion of the liver inevitably results in high rates of postopera-
tive complications and mortality. There are still controver-
sies on the optimal extent of hepatic resection to achieve a 
high percentage of R0 resection for hilar cholangiocarc- 
inoma. 
Combined major liver resection represents an aggressive 
surgical approach to remove a large volume of hepatic pa-
renchyma, including the use of right trisectionectomy, right 
hemihepatectomy, left trisectionectomy, or left hemihepa-
tectomy. This approach has widely been advocated as a 
prime choice of surgical treatment for hilar cholangiocarci-
noma, especially in patients with advanced tumors 
(Witzigmann et al., 2006). Combined major liver resection 
has the advantage of increasing surgical curability by ob-
taining wide and negative surgical resection margins 
(Nagino et al., 2006). In addition, hemihepatectomy/ 
trisectionectomy is technically feasible and can be per-
formed by many surgeons. The major drawback of com-
bined major liver resection is the small post-operative liver 
remnant, which is associated with high surgical morbidities 
and mortalities (Dinant et al., 2006). Thus, the increase in 
resectability rate can be offset by the increase in postopera-
tive mortality after major liver resection. 
A decrease in morbidity and mortality after liver resec-
tion is the key strategy for improving the results of surgical 
treatment of HC. Minor liver resection (three or fewer seg-
ments according to the Couinaud nomenclature) may be one 
way to resolve the problem. For early (T)-stage HC, minor 
resection of segments I, IVb and V has been performed to 
excise the tumor with adequate margins, termed “central 
liver resection”. 
We noticed that around 90% of the resected liver tissue 
was normal tissue, unaffected by the malignant tumor. We 
hypothesized that it would be possible to reduce the amount 
of resected liver tissue while ensuring the removal of the 
entire area by the tumor.  
Through pathological studies in 90 cases, we observed 
that hilar cholangiocarcinomas are typically 1–3 centimeters 
in diameter, often arising at the confluence of the left and 
right hepatic ducts and spreading only 2–8 millimeters 
along the bile duct wall. This finding indicated that resec-
tion of only about 20% of the liver would be necessary to 
treat the disease. Through clinical studies, we discovered 
that small volume liver resection significantly lowered 
post-operative rates of complications and mortality and we 
obtained similar long-term treatment outcomes compared to 
more extensive liver resection. In this prospective clinical 
study, 138 patients underwent resection with curative intent. 
Minor hepatectomy was performed in 93 patients with Bis-
muth-Corlette type I, II, or III HC without hepatic arterial or 
portal venous invasion, and major hepatectomy in 45 pa-
tients with type III HC with hepatic arterial or portal venous 
invasion, or type IV HC. Actuarial 1-, 3-, and 5-year sur-
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vival rates were 87%, 54%, and 34%, respectively, in the 
minor liver resection group, and 80%, 42% and 27% for 
major resection (P=0.300) (Figure 6). Major liver resection 
was associated with a higher operative morbidity rate than 
minor resection. Therefore, minor liver resection for HC, 
selected by predetermined criteria, had good results. Major 
liver resection should be reserved for Bismuth-Corlette type 
III HC with vascular invasion or type IV HC. 
In 2014, the Liver Surgery Group of the Surgical Branch 
of the Chinese Medical Association lead by Dr. Chen draft-
ed a consensus for the diagnosis and treatment of cholangi-
ocarcinoma (Chinese Chapter of International Hepato- 
Pancreato-Biliary et al., 2014), including HC. This consen-
sus lays down a foundation for establishing a guideline on 
diagnosis and treatment of cholangiocarcinoma in China. 
Inserting biliary-enteric anastomosis technique 
Another common challenge in hepatobiliary surgery is re-
lated to the surgical procedure known as biliary-enteric 
anastomosis performed on small bile ducts. The main diffi-
culty in minor liver resection for HC is biliary tract recon-
struction, because as many as 8–13 bile duct openings are 
left in the transection plane of the liver. In this situation, 
biliary tract reconstruction cannot be completed with tradi-
tional methods. Following numerous experiments, we es-
tablished an inserting biliary-enteric anastomosis technique 
and applied it to auxiliary partial orthotopic liver transplan-
tation and the reconstruction of the biliary tract when bile 
ducts are accidently injured during a prior biliary surgery 
(Yang et al., 2015). We later improved this technique by 
performing biliary-enteric anastomosis without stitching the 
anterior wall of the bile ducts—a useful modification for 
complex biliary operations, especially for the reconstruction 
of the biliary tract after central hepatectomy during hilar 
cholangiocarcinoma treatment. 
In the classical hepaticojejunostomy, the hepatic duct 
was anastomosed to the jejunum by using a mucosa-to- 
mucosa anastomosis. The operation is difficult for small  
bile ducts in the small operative space. The difficulty of the 
operation increases with decreases in the diameter of the 
bile ducts. In new intrahepatic cholangiojejunostomy, the 
posterior wall of the bile ducts is sutured to the posterior 
wall of the intestine, and then, the anterior wall of the intes-
tine is sutured to the liver transection plane. The operative 
space is large and vision is clear, making the operation rela-
tively simple (Figure 7). 
The new intrahepatic cholangiojejunostomy solves the 
problem of reconstruction of multiple small bile ductal 
openings after hepatobiliary resection. The procedure is 
safe, simple, and convenient, and it does not require place-
ment of a stent across the anastomosis. After the operation, 
the anastomotic stoma heals with low incidences of postop-
erative bile leak, excessive anastomotic stenosis, and symp-
tomatic postoperative obstructive jaundice and cholangitis 
(Yang et al., 2015). 
PANCREATIC DISEASE  
Invaginated pancreaticojejunostomy with transpancre-
atic U-sutures  
Pancreatoduodenectomy (PD) is the most effective therapy 
for treating malignant tumors at the head of the pancreas, 
the lower common bile duct, and the duodenum of the small 
intestine. A critical procedure in this operation is known as 
pancreaticojejunostomy (PJ), which currently involves 
time-consuming and complex stitching. The procedure is 
associated with a high incidence of postoperative pancreatic 
fistula (POPF), which may lead to postoperative mortality. 
The POPF rate ranges from 5% to 40%, even in specialized 
centers, depending on the definitions used (Cameron et al., 
2006). The POPF rate does not seem to have declined in the 
same way as the mortality rate has over the last few decades  
(Neoptolemos et al., 1997). Hemorrhage and sepsis are the 
most frequent sequels of POPF, both of which contribute to 
mortality (20%–40%) as well as to prolonged hospitaliza- 
 
 
Figure 6  (Color online) Minor liver resection for hilar cholangiocarcinoma. A, Resection plane after minor liver resection for HC. B, Kaplan-Meier overall 
survival curves for patients undergoing minor and major liver resection for hilar cholangiocarcinoma. P=0.300 (Chen et al., 2009). 
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Figure 7  (Color online) Diagram and intraoperative photograph of the inserting biliary-enteric anastomosis. A, Diagram of the inserting biliary-enteric 
anastomosis. B, The posterior wall of the jejunum has been anastomosed to the posterior biliary ductal wall. C, Anterior anastomosis has been completed by 
intermittent U suture between the jejunum and the edge of the liver transection plane. 
tion and increased hospital cost (Bottger and Junginger, 
1999; Trede and Schwall, 1988). 
POPF remains a major cause of postoperative morbidity, 
and it contributes significantly to mortality (Lai et al., 
2009). In an attempt to prevent postoperative complications, 
especially POPF, many refinements of procedures have 
been proposed. In the past 30 years, over 50 types of pan-
creatic and digestive tract reconstruction techniques have 
been reported. The increase in number of techniques of 
pancreatic and digestive tract reconstruction reflects the 
pancreatic surgeons’ continuous efforts to reduce complica-
tions of pancreatic surgery, aiming to refine pancreatic and 
digestive tract reconstruction so as to develop a better anas-
tomotic method to reduce complications after PD. On the 
other hand, the emergence of a variety of surgical methods 
indicates that there is currently no perfect method. The best 
pancreatic anastomosis technique after PD is still under  
debate. 
Invaginated pancreaticojejunostomy (IPJ) is performed 
by invagination of the pancreatic stump into the intestine in 
either an end-to-end or an end-to-side manner. For ease of 
performance, identification of the main pancreatic duct is 
not required, and in accordance with the physiological 
structure of the digestive tract, IPJ has been considered as 
the conventional and classic anastomosis method from the 
origin of the PD and is the most common type of PJ used 
nowadays. The incidence of postoperative complications 
has also been regarded as standard for evaluation of differ-
ent techniques. 
As reported in many publications, the POPF rate varies 
greatly in different reports in patients after IPJ because of 
variations in definitions used. In a review by Bassi et al., the 
incidence ranged between 9.9% and 28.5% and the different 
definitions used for pancreatic leakage resulted in highly 
significant differences across studies (Bassi et al., 2005). 
Other complications often occur after the onset of POPF. 
Post-operative bleeding due to erosion of peripancreatic 
vessels by extravasated pancreatic juice has been described 
in 2%–8% of cases (Rumstadt et al., 1998). The morbidity 
rate increased from 6% to 26% when POPF manifested 
(Zealley et al., 2006). 
In this context, we established a procedure described as 
invaginated pancreaticojejunostomy with transpancreatic U- 
sutures, which requires only two-to-four stitches and saves 
significant time with reliable effects (Figure 8). The real 
magic of the technique comes from the “automatic” inser-
tion of the pancreatic stump into the intestinal lumen simply 
by pulling the U-suture stitches—a process that cannot be 
achieved using any other pancreaticojejunostomy technique. 
The innovation has proven to be a breakthrough for pancre-
atoduodenectomy and pancreaticojejunostomy. 
In 1995, our group established the Chen’s U-stitch ap-
proach, which was a new technique of end-to-end invagi-
nated pancreaticojejunostomy with transpancreatic trans-
verse U-sutures after PD, and the preliminary results were 
quite encouraging at that time (Chen et al., 2009). In 88 
patients who underwent a transpancreatic U-sutures IPJ PD, 
only 2 patients (2.2%) developed a grade A POPF.  
Over the past 10 years, this technique has been used in 
264 patients who underwent pancreaticojejunostomy after 
PD, and excellent perioperative outcomes have been 
demonstrated. By 2014, a new clinical study including 264 
patients had been completed to further evaluate the clinical 
efficacy of this surgical approach (Chen et al., 2014). 
Among the patients who underwent transpancreatic U- 
sutures IPJ PD, postoperative morbidity was 22.3% 
(59/264) and mortality was 0% (0/264). The POPF rate was 
3.4% (9/264) for Grade A, 0.8% (2/264) for Grade B and 
0% (0/264) for Grade C. Therefore, the fistula-related mor-
bidity and mortality was largely avoided by using this new 
surgical technique. 
The pancreas is extremely prone to injury from a pancre-
atic fistula. Experience has shown that if there is even a 
small pinhole on the pancreas, a pancreatic fistula will oc-
cur. This is one of the main reasons for pancreatic fistula 
development after the traditional methods of pancreati-
cojejunostomy. The more the stitches used or pinholes cre-
ated during a PD procedure, the higher the probability of 
developing a pancreatic fistula. The low incidence of POPF 
following pancreaticojejunostomy with transpancreatic 
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Figure 8  (Color online) Invaginated pancreaticojejunostomy with 
transpancreatic U-sutures technique. A, Expose the anterior wall of the 
jejunal loop. At about 1.5 cm from the bowel resection margin near the 
mesentery, insert the needle from outside. Then, stitch the needle from 
inside to outside at about 0.5 cm from the bowel resection margin. B, Steer 
the needle to the pancreas. At about 1.5 cm from the stump of the lower 
edge of the pancreas, insert the needle from the ventral pancreas (front) and 
run through the pancreatic parenchyma to the dorsal pancreas (back). C, 
Steer the needle to the posterior wall of the jejunal loop. Insert the needle 
from outside at about 1.5 cm from the bowel resection margin and stitch 
through to the inside. Stitch horizontally from inside and exit the needle 
from about 1.0 cm of the insert pinhole. D, Steer the needle to the dorsal 
pancreas (back) of the lower edge. Insert the needle at about 0.8–1.0 cm of 
the first pinhole, run through the pancreatic parenchyma, and exit the nee-
dle from the ventral pancreas (front). E, Steer the needle to the anterior 
wall of the jejunal loop. Insert the needle at about 0.5 cm from bowel re-
section margin from the outside to the inside, and then exit the needle from 
the inside to the outside at 1.5 cm of the bowel resection margin. F–G, The 
first horizontal U shape Varus stitching is completed.  
transverse U-sutures described here is ascribed to the fol-
lowing four reasons: (i) it requires less dissection of the 
pancreatic stump, thus reducing the risk of pancreatic inju-
ry; (ii) there are fewer stitches (two to four U-sutures) and 
pinholes made within the pancreas; (iii) the full-thickness of 
the anterior and posterior walls of the jejunum loop presses 
on the pinholes of the pancreas after ligating the U-sutures, 
thus preventing the exudation of pancreatic juice from the 
pinholes and the occurrence of pancreatic fistula; and (iv) 
the pancreatic stump can be firmly invaginated into the je-
junum loop through transpancreatic transverse U-sutures. 
CONCLUSION 
In the past 30 years, great progress has been made in the 
treatment of HPB diseases owing to improved peri-    
operative management, better patient evaluation, improved 
surgical technique, and better understanding of anatomy.  
Most of our patients are found to have large HCC tumors 
or intermediate/advanced HCC at their first medical consul-
tation. Surgical resection remains the main treatment ap-
proach for large HCC tumors and intermediate/advanced 
HCC, and recent improvements in surgical techniques and 
peri-operative care have enhanced the feasibility and safety 
of liver resection, leading to favorable long-term outcomes 
in selected patients. However, there is no universal consen-
sus on the management of large HCC tumors and interme-
diate/advanced HCC in clinical practice. At Tongji Hospi-
tal, we have adopted a multidisciplinary approach to en-
hance long-term survival rates and to improve the quality of 
life of patients with HCC. 
The prognosis of malignancies in the pancreato-biliary 
system remains poor, and post-operative complications are 
relatively high. At Tongji Hospital, we carefully selected 
patients with pancreato-biliary tumors for surgical treat-
ment, and innovated biliary-enteric anastomosis and pan-
creas-enteric anastomosis to reduce complications. Further 
studies will focus on therapeutic strategies, such as com-
bined treatments, to reduce post-operative complications 
and improve long-term survival. 
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